Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”

Detalles Bibliográficos
Autores principales: Takahashi, Hirokazu, Anzai, Keizo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426383/
https://www.ncbi.nlm.nih.gov/pubmed/35531591
http://dx.doi.org/10.1002/hep4.1996
_version_ 1784778666873454592
author Takahashi, Hirokazu
Anzai, Keizo
author_facet Takahashi, Hirokazu
Anzai, Keizo
author_sort Takahashi, Hirokazu
collection PubMed
description
format Online
Article
Text
id pubmed-9426383
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-94263832022-08-31 Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD” Takahashi, Hirokazu Anzai, Keizo Hepatol Commun Correspondence John Wiley and Sons Inc. 2022-05-09 /pmc/articles/PMC9426383/ /pubmed/35531591 http://dx.doi.org/10.1002/hep4.1996 Text en © 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Correspondence
Takahashi, Hirokazu
Anzai, Keizo
Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
title Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
title_full Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
title_fullStr Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
title_full_unstemmed Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
title_short Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
title_sort reply to the letter to the editor “ipragliflozin improves the hepatic outcomes of patients with diabetes with nafld”
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426383/
https://www.ncbi.nlm.nih.gov/pubmed/35531591
http://dx.doi.org/10.1002/hep4.1996
work_keys_str_mv AT takahashihirokazu replytothelettertotheeditoripragliflozinimprovesthehepaticoutcomesofpatientswithdiabeteswithnafld
AT anzaikeizo replytothelettertotheeditoripragliflozinimprovesthehepaticoutcomesofpatientswithdiabeteswithnafld

Ejemplares similares